HBV markers in haemodialysis Brazilian patients: a prospective 12-month follow-up
Mem. Inst. Oswaldo Cruz
;
105(1): 107-108, Feb. 2010.
Artigo
em Inglês
| LILACS
| ID: lil-539309
ABSTRACT
The aim of this study was to determine the prevalence and the incidence of hepatitis B virus (HBV) among haemodialysis (HD) subjects and to evaluate whether testing for serological markers at the time of admission is suitable for HBV screening in this population. One hundred twenty-three patients belonging to two HD centres from São Paulo, Brazil, were tested prospectively. HBV DNA was detected by polymerase chain reaction (PCR) in each of the prospective subjects (n = 123) during one year. Additionally, all samples (n = 1,476) were analysed for HBV serological markers. The prevalence of hepatitis B core antibody (anti-HBc), hepatitis B surface antigen (HBsAg) and HBV DNA were 34.1 percent, 15.4 percent and 8.1 percent, respectively, while the incidence was null. Fluctuation in HBV serology was observed in one patient. Only 37.8 percent (17/45) of cases responded to the HBV vaccine. Our results suggest that employing more than one HBV marker and repeated follow-up evaluations may improve HBV screening in HD units.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Vírus da Hepatite B
/
Diálise Renal
/
Hepatite B
/
Anticorpos Anti-Hepatite B
/
Antígenos de Superfície da Hepatite B
Tipo de estudo:
Ensaio Clínico Controlado
/
Estudo de etiologia
/
Fatores de risco
Limite:
Humanos
País/Região como assunto:
América do Sul
/
Brasil
Idioma:
Inglês
Revista:
Mem. Inst. Oswaldo Cruz
Assunto da revista:
Medicina Tropical
/
Parasitologia
Ano de publicação:
2010
Tipo de documento:
Artigo
/
Documento de projeto
País de afiliação:
Brasil
Instituição/País de afiliação:
Instituto Adolfo Lutz/BR
/
Universidade de São Paulo/BR
Similares
MEDLINE
...
LILACS
LIS